Skip to content

Modified Tarsorrhaphy vs Gold Weight Implant for Paralytic Lagophthalmos in Leprosy Patients

Modified Tarsorrhaphy vs Gold Weight Implant Technique for Paralytic Lagophthalmos Treatment in Leprosy Patients: a Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04944498
Enrollment
19
Registered
2021-06-29
Start date
2019-05-09
Completion date
2021-04-04
Last updated
2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leprosy--Patients, Paralytic Lagophthalmos

Keywords

Hansen Disease, Leprosy, Paralytic lagophthalmos, Surgical intervention

Brief summary

This study aims to compare the effectivity and efficiency of Modified Tarsorrhaphy (MT) technique and Gold Weight Implant (GWI) technique as a surgical treatment of paralytic lagophthalmos in leprosy patients. The hypothesis is that MT technique is more effective and more efficient than GWI technique. This study used PROBE (Prospective Randomized Open-label Blinded-Endpoint) clinical trial. Samples consisted of 14 eyes in MT group and 13 eyes in GWI group as the control group. This study was conducted in 3 hospitals in Indonesia and the patients were observed in 1 year period.

Interventions

PROCEDUREModified Tarsorrhaphy

A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip

PROCEDUREGold Weight Implant

Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess

Sponsors

Yunia Irawati
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Treatment received by patients was randomized by research team members. The investigator as the oculoplastic surgeon (YI) acknowledged the treatment assigned to each patient based on randomization. Outcomes were measured by other oculoplastic surgeons with equal clinical experiences.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* paucibacillary (PB) or multibacillary (MB) type leprosy patient with unilateral/bilateral lagophthalmos who had not undergone eyelid reconstruction * patient aged 18 years old or older who could be performed surgery with local anesthesia

Exclusion criteria

* patient with acute leprosy reaction (\<6 months) and in steroid medication * patient with eyelid laxity \>8 mm

Design outcomes

Primary

MeasureTime frameDescription
Lagophthalmos distance without pressurePre-operativeEyelid margin distance in central, nasal, and temporal area measured in millimeters
Lagophthalmos distance with gentle pressurePre-operativeEyelid margin distance in central, nasal, and temporal area measured in millimeters after applying minimal pressure on upper eyelid
OSDI (Ocular Surface Disease Index)Pre-operativeQuestionnaire assessing subjective dry eyes symptoms
TBUT (Tear Break-Up Time)Pre-operativeExamination of tear break up time with fluorescein dye assessed with cobalt blue light from slit lamp
Schirmer test without anesthesiaPre-operativeTear film excretion examined using Whatman filter paper without anesthesia
Schirmer test with anesthesiaPre-operativeTear film excretion examined using Whatman filter paper with anesthesia prior to examination
EpitheliopathyPre-operativeEpitheliopathy occurence, assessed with fluorescent dye and observed with cobalt blue light filter of slit lamp
Corneal exposurePre-operativeExposed distance of cornea when the eye was closed
Corneal sensibilityPre-operativeSensibility measured in millimeters by using Luneau Cohcet-Bonnet Aesthesiometer
ComplicationintraoperativeComplication during surgery and after surgery
DurationIntraoperativeDuration of surgery
Cost1 year post-operativeCost of surgery

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026